# Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

> **NCT02341560** · PHASE2,PHASE3 · TERMINATED · sponsor: **Quark Pharmaceuticals** · enrollment: 732 (actual)

## Conditions studied

- Non Arteritic Anterior Ischemic Optic Neuropathy

## Interventions

- **DRUG:** QPI-1007 Injection - 1.5 mg
- **DRUG:** QPI-1007 Injection - 3.0 mg
- **OTHER:** Sham Injection Procedure

## Key facts

- **NCT ID:** NCT02341560
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-24
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 732 (ACTUAL)
- **Why stopped:** An interim analysis did not warrant to continue enrollment
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02341560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02341560, "Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT02341560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*